These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9949471)

  • 1. [Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism].
    Kirienko AI; Zolotukhin IA
    Ter Arkh; 1998; 70(11):78-80. PubMed ID: 9949471
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of venous thromboembolism after acute ischaemic stroke.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Sep; 370(9589):736; author reply 736-7. PubMed ID: 17765513
    [No Abstract]   [Full Text] [Related]  

  • 3. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 4. [Acute venous thrombosis: new directions in prophylaxis and treatment].
    Fedorov VD; Titiova MI; Ganzha PF
    Khirurgiia (Mosk); 1998; (12):60-3. PubMed ID: 9916443
    [No Abstract]   [Full Text] [Related]  

  • 5. Enoxaparin for the prevention of venous thromboembolism.
    Calderon EJ; Varela JM; Gonzalez de la Puente MA
    N Engl J Med; 2000 Jan; 342(2):136-7. PubMed ID: 10636758
    [No Abstract]   [Full Text] [Related]  

  • 6. Enoxaparin for the prevention of VT in acutely ill patients.
    Tseng CW; Huntington J
    J Fam Pract; 1999 Dec; 48(12):940-1. PubMed ID: 10628571
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prolongation of enoxaparin therapy to one month promotes recanalization of the occlusively thrombosed deep veins].
    Vorob'eva NM; Panchenko EP; Ermolina OV; Balakhonova TV; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(8):33-7. PubMed ID: 21961329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
    Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical application of enoxaparin.
    Hofmann T
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):321-37. PubMed ID: 15151480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why didn't this patient respond to enoxaparin?
    Porterfield LM
    RN; 1999 Apr; 62(4):95. PubMed ID: 10223064
    [No Abstract]   [Full Text] [Related]  

  • 16. [The prevention of postoperative deep venous thrombosis in orthopedic surgery].
    Rybachuk OI; Besiedyns'kyĭ SM; Huliaiev DV
    Lik Sprava; 1999 Sep; (6):95-9. PubMed ID: 10626456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is once- or twice-a-day enoxaparin as effective as unfractionated heparin for the treatment of venous thromboembolism (VTE)?
    Marsland T; Newton W
    J Fam Pract; 2001 May; 50(5):396. PubMed ID: 11350700
    [No Abstract]   [Full Text] [Related]  

  • 18. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
    Zufferey PJ; Samama CM; Rosencher N
    Thromb Haemost; 2010 Dec; 104(6):1083-4. PubMed ID: 20886198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.